Streetbeat News

Earnings

CCL

CUK

Carnival Corporation's shares are trading lower due to mixed results in the first quarter. The company's performance during this period has led to a decrease in stock price.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 1:47 pm

TSLA

A significant bearish sentiment has been observed in Tesla's (NASDAQ:TSLA) options market, as detected by Benzinga's options scanner. The scanner revealed 31 unusual options trades, with a sentiment split of 41% bullish and 58% bearish. The trades focus on a price band between $170.0 and $300.0 for Tesla. Notable options activity includes both bullish and bearish positions, with a total trade price for puts at $672,462 and calls at $993,520. Tesla's current market performance shows a 2.14% increase in stock price at $181.48, with an RSI indicating a neutral position. The next earnings report is expected in 21 days.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:46 pm

BKNG

Recent analysis of options trading for Booking Holdings (NASDAQ:BKNG) reveals a bullish trend among investors, with 58% of trades being bullish and 42% bearish. The trades include 4 puts and 8 calls, with a significant volume aiming for a strike price range between $2000.0 and $4800.0. The largest trades observed indicate a mix of bullish, bearish, and neutral sentiments, with the most notable being a bullish call sweep for a strike price of $3680.00, expiring on 01/16/26, valued at $1.1M. Booking Holdings, the world's largest online travel agency, is currently trading at $3661.08, with an upcoming earnings announcement in 36 days.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:46 pm

CCL

CUK

Carnival Corporation forecasts Q2 EPS of approximately $(0.03), aligning with estimates, and a full-year 2023 EPS of ~$0.98, slightly below the $0.99 estimate. The company anticipates capacity growth of 5.4% in Q2 2024 and 4.5% for the full year, with fuel expenses, including EUA, expected to reach $2.0 billion. Adjusted EBITDA is projected at approximately $5.63 billion for 2024, with an adjusted net income of about $1,280 million.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 1:42 pm

DRCT

DXYZ

GMDA

LIXT

MRDB

UNF

VLD

U.S. stocks traded higher with the Dow Jones gaining over 200 points. UniFirst Corporation reported weaker-than-expected Q2 earnings. Lixte Biotechnology, MariaDB, and Destiny Tech100 saw significant stock increases, while Gamida Cell, Direct Digital Holdings, and Velo3D experienced substantial declines. Oil prices fell slightly, while gold and silver prices increased.

Portfolio Pulse from Avi Kapoor

March 27, 2024 | 1:39 pm

NIO

NIO shares are trading lower following the company's announcement of a reduced delivery outlook for Q1.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 1:39 pm

EVAX

Evaxion Biotech (NASDAQ:EVAX) reported Q4 earnings, beating estimates with an EPS of $-0.16 versus the expected $-1.6, and revenue increased by $73 thousand from the previous year. Despite missing EPS estimates last quarter, the share price increased by 7% the following day.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:35 pm

ALT

BHVN

Altimmune Inc (NASDAQ:ALT) reported study results for obesity drug pemvidutide, showing 25.5% of weight loss from lean mass and 74.5% from adipose tissue. The company will present full data at an upcoming meeting. Despite Kerrisdale Capital's skepticism and competition from Biohaven (NASDAQ:BHVN), ALT shares rose 7.51% in premarket trading. Altimmune missed Q4 2023 EPS estimates and reported $198.0 million in cash and equivalents as of December 31, 2023.

Portfolio Pulse from Vandana Singh

March 27, 2024 | 1:31 pm

WMB

Williams Companies Inc. (NYSE:WMB) stock rose 1.58% to $38.69 in the current session, marking a 9.73% increase over the past month and a 31.55% increase over the past year. The company's P/E ratio is lower than the Oil, Gas & Consumable Fuels industry average, suggesting it might be undervalued despite its strong performance.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:30 pm

AURA

Aura Biosciences (NASDAQ:AURA) reported Q4 earnings, beating estimates with an EPS of $-0.5 against an expected $-1.82 but with no change in revenue from the previous year. The company had previously seen a 10% share price increase following last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:25 pm